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Tobacco and CVD: Challenges and Opportunities
Monika Arora , Christopher Millett ,§, K. Srinath Reddy 
New Delhi, India; and London, United KingdomCardiovascular diseases (CVDs) are the leading
causes of death and disability worldwide killing over
17 million people a year, with nearly 80% of these
deaths occurring in low- and middle-income coun-
tries (LMIC) [1]. The mortality due to CVDs is
projected to rise to 23.6 million by 2030 [2,3]. In
developed countries, age-adjusted CVD death rates
have declined in past decades as compared with a
stark increase in developing countries [4]. Tobacco
use is a major risk factor for CVDs and is responsi-
ble for 10% of associated global deaths [5]. As com-
pared with non-smokers, smokers experience 2 to
4-fold increased risk of coronary heart disease
(CHD) and cerebro-vascular stroke [6]. Smokeless
tobacco (SLT) use has been shown to be associated
with lipid abnormalities, hypertension, oxidative
stress and glucose intolerance, all of which are asso-
ciated with increased risk of CVDs [7]. Exposure to
secondhand smoke (SHS) is associated with 25–
30% increased risk of CHD among adults. A
majority (over 85%) of the adult deaths due to
exposure to SHS are due to CHD [1]. Unfortu-
nately, increasing rates of tobacco use in developing
countries are contributing significantly to the bur-
den of death and disability from CVDs. Moreover,
tobacco use impoverishes individuals and families
due to diversion of resources to buy tobacco, in-
creased health-care expenditure, and premature
death due to CVDs and other tobacco-related dis-
eases, which further burdens resources in poor
developing countries [8].
TOBACCO : A LOW PR I O R I T Y FOR
CARD I O LOG I S T S
Preventing CVD deaths caused by tobacco requires
a comprehensive multi-sectoral approach engagingFrom the Public Health Foundation of India, New Delhi, India; School of
Network for Chronic Disease, Public Health Foundation of India, New Dethe health systems, community, and the policymak-
ers. One of the most influential stakeholder groups
for effective tobacco control policies, treatment, and
prevention are health professionals such as cardiol-
ogists. Even though CVDs account for a major
share of tobacco-related morbidity and mortality,
cardiologists and their professional societies have
lagged behind in the crusade against tobacco. This
represents a missed opportunity to intervene among
CVD patients and at-risk groups. Studies have
shown that a structured course on tobacco control
is rarely included in medical curriculum [1]. Such
training among specialized health professionals,
such as cardiologists, is important as they are seen
as a credible source of vital information on the im-
pact of tobacco use and secondhand smoke to their
patients, public, and policymakers. Cardiologists
also have the potential to advocate for strong and
effective tobacco control policies as demonstrated
by the active involvement of South American Car-
diology Societies in defending Uruguay’s strong to-
bacco control policies (such as the comprehensive
smoke-free law) against attacks by the tobacco
industry, which resulted in outcomes such as re-
duced hospitalizations for myocardial infarctions
[1]. Thus, there is a need for continuing engage-
ment of cardiologists to improve cardiovascular
health through treatment of tobacco dependence,
prevention, cessation, and support for effective to-
bacco control thus strengthening research on the
health impact of tobacco use especially CVD im-
pact of SLT use and bringing about a policy level
change. Cardiologists need to highlight tobacco
use as a major cause of CVD-related morbidity
and mortality and actively support strong tobacco
control measures at the clinical, public health, and
policy levels [9].Public Health, Imperial College, London, United Kingdom; §South Asia
lhi, India. Correspondence: C. Millett (c.millett@imperial.ac.uk).
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Efforts to control tobacco use should be both pop-
ulation and individual based. Tobacco use was once
seen primarily as a problem of individual behavior,
to be addressed at the individual level through
interventions such as smoking cessation and health
behavior programs but evidence now clearly points
that population and policy level changes have a
measurable influence on health outcomes. Popula-
tion-level tobacco control interventions have the
potential to benefit more disadvantaged segments
of the society and thereby contribute to reducing
health inequalities [10]. Beyond the direct impact
of these types of population-level interventions,
the resulting changes in social attitudes and norms
towards tobacco use also affect overall tobacco use.
For example, although smoke-free legislations are
primarily aimed at protecting the nonsmokers, they
also help decrease smoking prevalence and alter the
societal norms such as acceptability to smoking in
public places. The World Health Organization
has identified a set of evidence-based ‘‘best buy’’
population-level interventions that are not only
highly cost-effective but also feasible and appropri-
ate to implement within the local constraints of the
LMICs. These four key cost-effective policies in-
clude: tax increases on tobacco products, smoke-free
indoor workplaces and public places, health infor-
mation and warnings about tobacco, and bans on
tobacco advertising and promotion [11].
Health professionals, such as cardiologists, need
to be engaged as they have a major role in all set-
tings–policy making, as well as clinical settings,
thereby minimizing missed opportunities in tobac-
co cessation. Brief advice from physicians encour-
age patients to think about quitting and leads to
quit attempts, thereby increasing the quit rate by
a further 1–3% [12]. Physicians offering basic quit
advice could prevent about 13% of myocardial
infarctions and 19% of strokes [13]. In many coun-
tries smokeless tobacco is promoted as a safer alter-
native to smoking as a ‘harm reduction’ strategy.
However, research studies now show that SLT
use is associated with adverse cardiovascular effects,
which needs further investigation.AR T I C L E S I N TH I S I S S U E O F G LOBA L
H EA R T
The UN High Level Meeting on NCDs held in
September 2011 recommended accelerated imple-mentation of the Framework Convention on To-
bacco Control (FCTC). Given the raised profile
of tobacco control internationally, and the impor-
tant role of cardiologists, this issue of Global Heart
provides a timely update on the clinical, research,
and policy perspectives of tobacco and cardiovascu-
lar disease. The issue contains a fascinating article
on the history of tobacco use and a series of articles
on the pathophysiological and clinical aspects of to-
bacco and cardiovascular disease. We know that
smoking or exposure to SHS cause cardiovascular
diseases. However, the mechanisms by which it oc-
curs are not completely understood. ‘‘Pathophysio-
logical mechanisms of tobacco-related CVD’’
reviews these mechanisms. The article first reviews
the role of various components of tobacco smoke in
cardiovascular disease including nicotine, carbon
monoxide, and oxidant gases. It then goes on to de-
scribe the postulated pathophysiological pathways
leading to the development of atherothrombosis.
An article on metabolic and inflammatory path-
ways to CVD risk is also presented. ‘‘Tobacco ces-
sation approaches and impact on CVD,’’ analyzes
the potential benefit of smoking cessation in
CVD patients. The article also analyzes the impact
of different cessation techniques including various
psychosocial interventions and pharmacotherapy.
Not only smoking, but also smokeless tobacco
product use has been implicated to cause CVDs.
Children and infants are particularly vulnerable
to SHS exposure as they cannot escape it, especially
if their parents smoke in their presence. ‘‘Pediatric
secondhand smoke exposure: systematic multilevel
strategies to improve health,’’ discusses integrated
multi-level approaches for effectively reducing
pediatric SHSe. This involves family-, healthcare
provider-, community- and wider population-level
interventions, while building linkages across levels
of intervention to facilitate synergistic intervention
effects.
We also present a series of articles on some
important areas of tobacco and CVD research.
‘‘Smoke-free air: an important strategy to reduce
heart attacks,’’ highlights the substantial public
health of smoke-free public places found in re-
cent meta-analyses but reminds us that only
11% of the world’s population are covered by
comprehensive smoke-free legislation suggesting
there is much work to do still. Another article
provides a review of the current evidence on
the role of mobile phones in smoking cessation.
The article finds that emerging evidence suggests
mobile phones could be a valuable tool for the
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97delivery of smoking cessation interventions in
both low-and high-income settings, even to
historically hard-to-reach groups due to high
penetration of mobile phones across all socioeco-
nomic groups. We also have two articles high-
light both ‘old’ and ‘new’ threats from
noncigarette tobacco use. The growing use of
the waterpipe and e-cigarettes globally, highlights
the need to adapt our surveillance tools to
include non-cigarette tobacco use and develop
evidence-based interventions to complement
existing strategies, which are currently largely
focused on cigarette use. The ongoing threat
posed by bidi use, particularly in South Asia,
underline the importance of effective advocacy
to rapidly address the generally very low taxation
levels on this product. The articles show that
more high-quality epidemiological and policy rel-
evant research on noncigarette forms of tobacco
is an important priority.
We also present articles that focus on some of
the key policy issues. ‘‘Death and taxes: epidemio-
logical and economic evidence on smoking,’’ dis-
cusses the need of raising taxes in LMICs to
reduce tobacco use and associated CVD mortality.
While per adult consumption of cigarettes has
more than halved in the last three decades in the
United States, United Kingdom (UK), Canada,
France, and other high-income countries (HICs),
male smoking has risen sharply in many LMICs
such as China and Indonesia. Tax increase played
a major role in reducing smoking in HICs. But,
this greatly effective tool remains underutilized in
LMICs. Authors suggest that tripling taxes on to-
bacco could rapidly raise cessation rates and deter
smoking initiation, and could avoid premature
deaths worldwide.
Not only smoking, but also exposure to SHS
leads to significant cardiovascular morbidity and
mortality. ‘‘Secondhand smoke and CVD in low-
and middle-income countries, a case for action,’’analyzes SHS exposure (SHSe) in LMICs on the
basis of Global Adult Tobacco Survey data from
14 LMICs. Data reveal high SHSe in LMICs,
especially among women. The authors also con-
ducted a systematic review of studies on SHS expo-
sure and CVD risk in LMICs. Eight papers
reported the association of SHS with ischemic
heart disease and four reported the association of
SHS with stroke. The article concludes with a def-
inite case for action by governments in LMICs to
implement smoke-free laws and protect their citi-
zens from SHS-induced CVDs. ‘‘Global tobacco
surveys: information for action by cardiologists,’’
discusses the importance of timely surveillance on
tobacco use and highlights the important contribu-
tion of surveys within the Global Tobacco Surveil-
lance System, particularly the Global Adult
Tobacco Survey (GATS) and the Global Youth
Tobacco Survey (GYTS), have added to our
understanding of the tobacco epidemic in low-
and middle-income countries. The final two arti-
cles focus on adolescent smoking. ‘‘Health promo-
tion for primordial prevention of tobacco use,’’
discusses the range of interventions that may be
effective in reducing adolescent smoking and an-
other article by Pranay Lal and colleagues contro-
versially calls for the legal age for tobacco
purchase to be raised to 21 years in India.
In summary, we hope that this special issue
provides an informative and comprehensive over-
view of the clinical, research, and policy aspects
of tobacco use as related to cardiovascular dis-
ease. It is important that cardiologists respond
to the challenges and opportunities presented by
the tobacco epidemic to improve cardiovascular
health of patients and communities through evi-
dence-based clinical practice (by delivering cessa-
tion interventions), in research and by providing
vital leadership and support for effective local,
national, and international tobacco control
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